No Red Tape For Addiction Treatment Act

Bill Number

S. 3522

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-12-17: Read twice and referred to the Committee on Finance.

Last Updated

2026-01-12T16:10:10Z

AI-Generated Summary

Purpose

The "No Red Tape For Addiction Treatment Act" (S. 3522) aims to improve access to medication-assisted treatment (MAT) for opioid use disorder (OUD) under Medicaid by removing certain administrative barriers. MAT refers to FDA-approved medications, like buprenorphine or methadone, combined with counseling to treat OUD. The bill ensures that states cannot impose prior authorization (a requirement for approval before providing a drug) or dosage limits on at least one version of these medications.

Key Provisions

• Mandatory Coverage Without Barriers: State Medicaid plans must cover at least one formulation (e.g., pill, patch, or injection) of each type of MAT drug or biological product approved for OUD treatment. This coverage must be free from prior authorization or dosage restrictions. If a long-lasting injectable version exists, it must be included as an option.
• Preservation of State Flexibility: States can still maintain their preferred drug lists (formularies), as long as they comply with existing federal rules under Section 1927(d)(4) of the Social Security Act, which allows states to limit coverage to specific drugs for cost control.
• Effective Date: Changes apply to medical assistance provided one year after the bill's enactment. States that need new laws to comply get extra time—until the first calendar quarter after their next legislative session ends.
• Reporting Requirement: The Medicaid and CHIP Payment and Access Commission (MACPAC), an independent advisory body, must submit a report to Congress within one year of enactment. The report will analyze:
• How states use management controls (e.g., dosing limits, age restrictions, counseling mandates, or mental health screenings) for MAT under Medicaid.
• The administrative burden these controls place on doctors and providers.
• Other federal or state Medicaid policies that hinder patient access to MAT or complicate prescribing.

Significant Changes to Existing Law

• Amends Section 1905(ee) of the Social Security Act to add a new paragraph requiring barrier-free coverage for at least one MAT formulation, expanding on current rules that already promote MAT access but allow states more leeway on restrictions.
• Updates Section 1927(d)(1)(A) to explicitly exempt the new requirements from general state authority over drug coverage, preventing states from using prior authorization or dosage limits on the mandated formulations.
• These changes build on prior efforts to address the opioid crisis but specifically target Medicaid's utilization management tools, which can delay or deny treatment.

Potential Impacts

• On Citizens: Medicaid enrollees with OUD (over 2 million affected annually) could gain faster, easier access to essential medications, potentially improving treatment adherence, reducing overdose risks, and supporting recovery without added hurdles.
• On Government Agencies: State Medicaid programs must update their plans and systems to comply, increasing administrative workload initially but possibly lowering long-term costs from untreated OUD (e.g., fewer emergency visits). The Centers for Medicare & Medicaid Services (CMS) will enforce compliance, while MACPAC's report could inform future policy adjustments. No direct impact on international relations.
• Broader Effects: May reduce the overall burden of the opioid epidemic by standardizing access across states, though it does not address non-Medicaid populations or non-MAT treatments.

Main Stakeholders Affected

• Medicaid Beneficiaries with OUD: Primary beneficiaries, as they gain unrestricted access to treatments.
• Healthcare Providers and Clinicians: Benefit from reduced paperwork and delays in prescribing MAT, easing administrative burdens.
• State Medicaid Agencies: Must revise coverage policies, potentially facing short-term compliance costs but long-term savings from better OUD management.
• Pharmaceutical Manufacturers: Could see increased demand for specific MAT formulations, especially injectables.
• Federal Government (CMS and MACPAC): Oversees implementation and provides data-driven insights via the required report.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens federal oversight of state Medicaid plans under Title XIX of the Social Security Act, ensuring uniform minimum access to OUD treatments without infringing on states' rights to manage formularies. The delayed effective date for states needing legislation respects federalism by avoiding immediate penalties.
• Constitutional: Aligns with the Spending Clause (Article I, Section 8), as Medicaid is a federal-state partnership where states accept conditions for funding; no apparent conflicts with equal protection or due process.
• Political: Introduced bipartisanship (by Senators Hassan (D-NH) and Justice (R-WV)) reflects urgency around the opioid crisis, a nonpartisan public health issue. The bill could set a precedent for reducing red tape in other Medicaid-covered treatments, influencing future debates on healthcare access versus cost control.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Hassan, Margaret Wood [D-NH]

Cosponsors (1)

Sen. Justice, James C. [R-WV]

Recent Actions

• 2025-12-17: Read twice and referred to the Committee on Finance.
• 2025-12-17: Introduced in Senate

Bill Versions

• No Red Tape For Addiction Treatment Act — issued 2025-12-17 — PDF (5 pages)